Form 4: Encompass Health EVP Douglas Coltharp Reports Stock Option Grant

Encompass Health's EVP & Chief Financial Officer, Douglas Coltharp, reported the grant of non-qualified stock options exercisable over three years, commencing March 1, 2025.

Summary

• Douglas E. Coltharp, EVP & Chief Financial Officer of Encompass Health Corp, filed a Form 4.
• The filing reports the grant of non-qualified stock options.
• The options allow Coltharp to purchase 14,735 shares of Encompass Health common stock at an exercise price of $74.20.
• The options vest in equal annual installments over a three-year period, starting March 1, 2025.
• The expiration date for the options is March 1, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of executive compensation, which is neither particularly positive nor negative.

Positives

• The grant of stock options aligns the executive's interests with those of the shareholders, incentivizing performance and long-term value creation.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the stock options.

Industry Context

Stock option grants are a common form of executive compensation in the healthcare industry, used to attract and retain talent and align management's interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages across various industries, including healthcare.
• Companies like HCA Healthcare and Universal Health Services also utilize stock options as part of their executive compensation plans.
• The vesting schedule and exercise price are typical for such grants, aligning with industry norms for incentivizing long-term performance.

Stakeholder Impact

• The stock option grant could potentially impact shareholders by diluting equity if the options are exercised.
• The grant incentivizes the executive to improve company performance, which could benefit shareholders.

Key Dates